Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial

Abstract Aims/Introduction Recent clinical trials on sodium–glucose cotransporter 2 inhibitors showed improved outcomes in patients with type 2 diabetes at a high risk of cardiovascular events. However, the underlying effects on endothelial function remain unclear. Materials and Methods The effect o...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R. Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda, Yasushi Matsuzawa, Hirofumi Tomiyama, Minako Yamaoka‐Tojo, Shinichiro Ueda, Yukihito Higashi, Koichi Node
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Journal of Diabetes Investigation
Subjects:
Cardiovascular disease
Empagliflozin
Endothelial function
Online Access:https://doi.org/10.1111/jdi.13289

Internet

https://doi.org/10.1111/jdi.13289

Similar Items